PAKIANATHAN DEEPIKA

SEC source: 0001270734-26-000007 · form4-09252026_120922.xml · derivative · entry 9

PAKIANATHAN DEEPIKA · CIK 0001270734 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Ordinary Shares · 13,398 shares

Expires 2036-06-11

F3 · price: At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a "Company Option"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option. However, any Company Option that has an exercise price per Ordinary Share that is greater than or equal to the Per Share Cash Consideration was cancelled and ceased to exist and the holder of any such Company Option was not entitled to payment of any consideration therefor.

F3 · derivative.exercise_date: At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a "Company Option"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option. However, any Company Option that has an exercise price per Ordinary Share that is greater than or equal to the Per Share Cash Consideration was cancelled and ceased to exist and the holder of any such Company Option was not entitled to payment of any consideration therefor.

SEC source: 0001270734-26-000007 · form4-09252026_120922.xml · derivative · entry 8

PAKIANATHAN DEEPIKA · CIK 0001270734 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Ordinary Shares · 24,258 shares

Expires 2035-05-18

F3 · price: At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a "Company Option"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option. However, any Company Option that has an exercise price per Ordinary Share that is greater than or equal to the Per Share Cash Consideration was cancelled and ceased to exist and the holder of any such Company Option was not entitled to payment of any consideration therefor.

F3 · derivative.exercise_date: At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a "Company Option"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option. However, any Company Option that has an exercise price per Ordinary Share that is greater than or equal to the Per Share Cash Consideration was cancelled and ceased to exist and the holder of any such Company Option was not entitled to payment of any consideration therefor.

SEC source: 0001270734-26-000007 · form4-09252026_120922.xml · derivative · entry 7

PAKIANATHAN DEEPIKA · CIK 0001270734 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Ordinary Shares · 23,576 shares

Expires 2034-05-07

F3 · price: At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a "Company Option"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option. However, any Company Option that has an exercise price per Ordinary Share that is greater than or equal to the Per Share Cash Consideration was cancelled and ceased to exist and the holder of any such Company Option was not entitled to payment of any consideration therefor.

F3 · derivative.exercise_date: At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a "Company Option"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option. However, any Company Option that has an exercise price per Ordinary Share that is greater than or equal to the Per Share Cash Consideration was cancelled and ceased to exist and the holder of any such Company Option was not entitled to payment of any consideration therefor.

SEC source: 0001270734-26-000007 · form4-09252026_120922.xml · derivative · entry 6

PAKIANATHAN DEEPIKA · CIK 0001270734 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Ordinary Shares · 22,044 shares

Expires 2033-05-01

F3 · price: At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a "Company Option"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option. However, any Company Option that has an exercise price per Ordinary Share that is greater than or equal to the Per Share Cash Consideration was cancelled and ceased to exist and the holder of any such Company Option was not entitled to payment of any consideration therefor.

F3 · derivative.exercise_date: At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a "Company Option"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option. However, any Company Option that has an exercise price per Ordinary Share that is greater than or equal to the Per Share Cash Consideration was cancelled and ceased to exist and the holder of any such Company Option was not entitled to payment of any consideration therefor.

SEC source: 0001270734-26-000007 · form4-09252026_120922.xml · derivative · entry 5

PAKIANATHAN DEEPIKA · CIK 0001270734 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Ordinary Shares · 28,000 shares

Expires 2032-04-25

F3 · price: At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a "Company Option"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option. However, any Company Option that has an exercise price per Ordinary Share that is greater than or equal to the Per Share Cash Consideration was cancelled and ceased to exist and the holder of any such Company Option was not entitled to payment of any consideration therefor.

F3 · derivative.exercise_date: At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a "Company Option"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option. However, any Company Option that has an exercise price per Ordinary Share that is greater than or equal to the Per Share Cash Consideration was cancelled and ceased to exist and the holder of any such Company Option was not entitled to payment of any consideration therefor.

SEC source: 0001270734-26-000007 · form4-09252026_120922.xml · derivative · entry 4

PAKIANATHAN DEEPIKA · CIK 0001270734 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Ordinary Shares · 6,000 shares

Expires 2031-04-26

F3 · price: At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a "Company Option"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option. However, any Company Option that has an exercise price per Ordinary Share that is greater than or equal to the Per Share Cash Consideration was cancelled and ceased to exist and the holder of any such Company Option was not entitled to payment of any consideration therefor.

F3 · derivative.exercise_date: At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a "Company Option"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option. However, any Company Option that has an exercise price per Ordinary Share that is greater than or equal to the Per Share Cash Consideration was cancelled and ceased to exist and the holder of any such Company Option was not entitled to payment of any consideration therefor.

SEC source: 0001270734-26-000007 · form4-09252026_120922.xml · derivative · entry 3

PAKIANATHAN DEEPIKA · CIK 0001270734 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Ordinary Shares · 17,000 shares

Expires 2030-06-30

F3 · price: At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a "Company Option"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option. However, any Company Option that has an exercise price per Ordinary Share that is greater than or equal to the Per Share Cash Consideration was cancelled and ceased to exist and the holder of any such Company Option was not entitled to payment of any consideration therefor.

F3 · derivative.exercise_date: At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a "Company Option"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option. However, any Company Option that has an exercise price per Ordinary Share that is greater than or equal to the Per Share Cash Consideration was cancelled and ceased to exist and the holder of any such Company Option was not entitled to payment of any consideration therefor.

SEC source: 0001270734-26-000007 · form4-09252026_120922.xml · nonDerivative · entry 2

PAKIANATHAN DEEPIKA · CIK 0001270734 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

F2 · price: At the Effective Time, pursuant to the Merger Agreement, each award of restricted stock units of the Issuer (a "Company RSU Award") that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the Per Share Cash Consideration multiplied by (ii) the number of Ordinary Shares underlying such Company RSU Award (subject to any required tax withholdings as provided in the Merger Agreement) plus (iii) one CVR for each Ordinary Share underlying such Company RSU Award.

SEC source: 0001270734-26-000007 · form4-09252026_120922.xml · nonDerivative · entry 1

PAKIANATHAN DEEPIKA · CIK 0001270734 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,009

F1 · price: On September 23, 2026, pursuant to that certain Agreement and Plan of Merger (the "Merger Agreement"), dated June 28, 2026, by and among the Issuer, Zymeworks Inc. ("Parent"), and Zymeworks Merger Sub 1, a wholly owned subsidiary of Parent, the Issuer became a wholly owned subsidiary of Parent (the "Merger"). At the effective time of the Merger (the "Effective Time"), pursuant to the Merger Agreement, each ordinary share, par value $0.00001 per share, of the Issuer ("Ordinary Share") held by the reporting person as of immediately prior to the Effective Time was cancelled and converted into the right to receive (i) $17.00 in cash, without interest (the "Per Share Cash Consideration") and (ii) one contingent value right (a "CVR"). Each CVR represents a non-tradeable contractual contingent right to receive cash payments based on the achievement of certain commercial milestones following the Effective Time.

SEC source: 0001270734-26-000004 · form4-06172026_010650.xml · derivative · entry 2

PAKIANATHAN DEEPIKA · CIK 0001270734 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,398

Underlying: Ordinary Shares · 13,398 shares

Expires 2036-06-11

F1 · derivative.exercise_date: This option may be exercised and shall be vested as to 1/12th of the shares subject to this option when optionee completes each continuous month of service following the grant date and any then remaining unvested shares shall vest on the date of the next annual meeting of the company's shareholders provided the optionee remains in continuous service on such date.

SEC source: 0001270734-26-000004 · form4-06172026_010650.xml · nonDerivative · entry 1

PAKIANATHAN DEEPIKA · CIK 0001270734 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 64,074

SEC source: 0001270734-26-000002 · ownership.xml · nonDerivative · entry 1

PAKIANATHAN DEEPIKA · CIK 0001270734 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,508

F1 · shares: Represents the award of restricted stock units ("RSUs") pursuant to the Karyopharm Therapeutics Inc. 2022 Equity Incentive Plan, as amended. RSUs convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. The RSUs vest 100% on May 21, 2027; however, delivery of the shares is deferred until the earlier of (a) the date of the director's separation from service to Karyopharm Therapeutics Inc. and (b) a change-in-control event.

SEC source: 0001193125-26-082818 · ownership.xml · derivative · entry 1

PAKIANATHAN DEEPIKA · CIK 0001270734 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 66,000

Underlying: American Depositary Shares · 66,000 shares

Expires 2036-02-26

F1 · derivative.exercise_date: Vests in substantially equal monthly installments over a one year period from the February 26, 2026 grant date.

F2 · derivative.underlying: Each American Depositary Share ("ADS") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer.

SEC source: 0000950170-25-078961 · ownership.xml · derivative · entry 1

PAKIANATHAN DEEPIKA · CIK 0001270734 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,600

Underlying: Common Stock · 4,600 shares

Expires 2035-05-27

F1 · derivative.exercise_price: Amounts reported in this Form 4 reflect the one-for-fifteen reverse stock split effected by the Issuer on February 25, 2025.

F1 · shares: Amounts reported in this Form 4 reflect the one-for-fifteen reverse stock split effected by the Issuer on February 25, 2025.

F2 · derivative.exercise_date: This option vests as to 100% of the underlying shares on May 28, 2026.

F1 · derivative.underlying_shares: Amounts reported in this Form 4 reflect the one-for-fifteen reverse stock split effected by the Issuer on February 25, 2025.

F1 · balance_after: Amounts reported in this Form 4 reflect the one-for-fifteen reverse stock split effected by the Issuer on February 25, 2025.

SEC source: 0001415889-25-014022 · form4-05212025_110510.xml · derivative · entry 2

PAKIANATHAN DEEPIKA · CIK 0001270734 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 24,258

Underlying: Ordinary Shares · 24,258 shares

Expires 2035-05-18

F1 · derivative.exercise_date: This option may be exercised and shall be vested as to 1/12th of the shares subject to this option when optionee completes each continuous month of service following the grant date and any then remaining unvested shares shall vest on the date of the next annual meeting of the company's shareholders provided the optionee remains in continuous service on such date.

SEC source: 0001415889-25-014022 · form4-05212025_110510.xml · nonDerivative · entry 1

PAKIANATHAN DEEPIKA · CIK 0001270734 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 58,065

SEC source: 0000950170-25-015423 · ownership.xml · derivative · entry 1

PAKIANATHAN DEEPIKA · CIK 0001270734 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 55,000

Underlying: American Depositary Shares · 55,000 shares

Expires 2035-02-05

F1 · derivative.exercise_date: Vests in substantially equal monthly installments over a one year period from the February 5, 2025 grant date

F2 · derivative.underlying: Each American Depositary Share ("ADS") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer

SEC source: 0000950170-24-100281 · ownership.xml · derivative · entry 13

PAKIANATHAN DEEPIKA · CIK 0001270734 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 30,000

Underlying: American Depository Shares · 15,000 shares

Expires 2034-02-08

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F9 · derivative.exercise_date: Vests in substantially equal monthly installments over a one year period from the February 8, 2024 grant date. As of June 8, 2024, 15,000 Share Options have vested.

F1 · derivative.underlying: Each American Depositary Share ("ADS") represents five ordinary shares of the Issuer.

SEC source: 0000950170-24-100281 · ownership.xml · derivative · entry 12

PAKIANATHAN DEEPIKA · CIK 0001270734 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: American Depository Shares · 55,000 shares

Expires 2033-02-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F8 · derivative.exercise_date: Vested in substantially equal monthly installments over a one year period from the February 1, 2023 grant date.

F1 · derivative.underlying: Each American Depositary Share ("ADS") represents five ordinary shares of the Issuer.

SEC source: 0000950170-24-100281 · ownership.xml · derivative · entry 11

PAKIANATHAN DEEPIKA · CIK 0001270734 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: American Depository Shares · 55,000 shares

Expires 2032-02-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F7 · derivative.exercise_date: Vested in substantially equal monthly installments over a one year period from the February 1, 2022 grant date.

F1 · derivative.underlying: Each American Depositary Share ("ADS") represents five ordinary shares of the Issuer.

SEC source: 0000950170-24-100281 · ownership.xml · derivative · entry 10

PAKIANATHAN DEEPIKA · CIK 0001270734 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: American Depository Shares · 31,500 shares

Expires 2031-02-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F6 · derivative.exercise_date: Vested in substantially equal monthly installments over a one year period from the February 1, 2021 grant date.

F1 · derivative.underlying: Each American Depositary Share ("ADS") represents five ordinary shares of the Issuer.

SEC source: 0000950170-24-100281 · ownership.xml · derivative · entry 9

PAKIANATHAN DEEPIKA · CIK 0001270734 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: American Depository Shares · 11,000 shares

Expires 2030-02-20

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_date: Vested in substantially equal monthly installments over a one year period from the February 20, 2020 grant date.

F1 · derivative.underlying: Each American Depositary Share ("ADS") represents five ordinary shares of the Issuer.

SEC source: 0000950170-24-100281 · ownership.xml · derivative · entry 8

PAKIANATHAN DEEPIKA · CIK 0001270734 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: American Depository Shares · 5,500 shares

Expires 2029-07-23

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: Vested in substantially equal monthly installments over a one year period from the July 23, 2019 grant date.

F1 · derivative.underlying: Each American Depositary Share ("ADS") represents five ordinary shares of the Issuer.

SEC source: 0000950170-24-100281 · ownership.xml · nonDerivative · entry 7

PAKIANATHAN DEEPIKA · CIK 0001270734 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

F1 · security: Each American Depositary Share ("ADS") represents five ordinary shares of the Issuer.

F2 · shares: Sale is due to fund administration reasons.

F3 · price: The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $4.360 to $4.495, inclusive. The Reporting Person undertakes to provide to Mereo BioPharma Group plc ("Mereo"), any security holder of Mereo, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of ADSs sold at each separate price within the ranges set forth in footnote (3) to this Form

SEC source: 0000950170-24-100281 · ownership.xml · nonDerivative · entry 6

PAKIANATHAN DEEPIKA · CIK 0001270734 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 105,244

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: Each American Depositary Share ("ADS") represents five ordinary shares of the Issuer.

SEC source: 0000950170-24-100281 · ownership.xml · nonDerivative · entry 5

PAKIANATHAN DEEPIKA · CIK 0001270734 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 103,173

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: Each American Depositary Share ("ADS") represents five ordinary shares of the Issuer.

SEC source: 0000950170-24-100281 · ownership.xml · nonDerivative · entry 4

PAKIANATHAN DEEPIKA · CIK 0001270734 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 59,688

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: Each American Depositary Share ("ADS") represents five ordinary shares of the Issuer.

SEC source: 0000950170-24-100281 · ownership.xml · nonDerivative · entry 3

PAKIANATHAN DEEPIKA · CIK 0001270734 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,735

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: Each American Depositary Share ("ADS") represents five ordinary shares of the Issuer.

SEC source: 0000950170-24-100281 · ownership.xml · nonDerivative · entry 2

PAKIANATHAN DEEPIKA · CIK 0001270734 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,317

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: Each American Depositary Share ("ADS") represents five ordinary shares of the Issuer.

SEC source: 0000950170-24-100281 · ownership.xml · nonDerivative · entry 1

PAKIANATHAN DEEPIKA · CIK 0001270734 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,825

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: Each American Depositary Share ("ADS") represents five ordinary shares of the Issuer.

SEC source: 0000950170-24-070991 · ownership.xml · nonDerivative · entry 6

PAKIANATHAN DEEPIKA · CIK 0001270734 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 0

F3 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $0.9303 to $0.965, inclusive. The Reporting Person has provided to the issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price within the range.

F5 · ownership.nature: The shares are held directly by Delphi BioInvestments VIII, L.P. ("DB VIII"). DMP VIII is the general partner of each of DB VIII and DV VIII. The Reporting Person is a managing member of DMP VIII. As a managing member of DMP VIII, the Reporting Person shares voting and investment power over the securities held by DB VIII and DV VIII, and may be deemed to have indirect beneficial ownership of such shares. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his proportionate pecuniary interest therein.

SEC source: 0000950170-24-070991 · ownership.xml · nonDerivative · entry 5

PAKIANATHAN DEEPIKA · CIK 0001270734 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 0

F3 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $0.9303 to $0.965, inclusive. The Reporting Person has provided to the issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price within the range.

F4 · ownership.nature: The shares are held directly by Delphi Ventures VIII, L.P. ("DV VIII"). Delphi Management Partners VIII, L.L.C. ("DMP VIII"), is the general partner of each of DB VIII and DV VIII. The Reporting Person is a managing member of DMP VIII. As a managing member of DMP VIII, the Reporting Person shares voting and investment power over the securities held by DB VIII and DV VIII, and may be deemed to have indirect beneficial ownership of such shares. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his proportionate pecuniary interest therein.

SEC source: 0000950170-24-070991 · ownership.xml · nonDerivative · entry 4

PAKIANATHAN DEEPIKA · CIK 0001270734 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 2,240

F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $0.97 to $1.0302, inclusive. The Reporting Person has provided to the issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price within the range.

F5 · ownership.nature: The shares are held directly by Delphi BioInvestments VIII, L.P. ("DB VIII"). DMP VIII is the general partner of each of DB VIII and DV VIII. The Reporting Person is a managing member of DMP VIII. As a managing member of DMP VIII, the Reporting Person shares voting and investment power over the securities held by DB VIII and DV VIII, and may be deemed to have indirect beneficial ownership of such shares. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his proportionate pecuniary interest therein.

SEC source: 0000950170-24-070991 · ownership.xml · nonDerivative · entry 3

PAKIANATHAN DEEPIKA · CIK 0001270734 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 229,308

F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $0.97 to $1.0302, inclusive. The Reporting Person has provided to the issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price within the range.

F4 · ownership.nature: The shares are held directly by Delphi Ventures VIII, L.P. ("DV VIII"). Delphi Management Partners VIII, L.L.C. ("DMP VIII"), is the general partner of each of DB VIII and DV VIII. The Reporting Person is a managing member of DMP VIII. As a managing member of DMP VIII, the Reporting Person shares voting and investment power over the securities held by DB VIII and DV VIII, and may be deemed to have indirect beneficial ownership of such shares. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his proportionate pecuniary interest therein.

SEC source: 0000950170-24-070991 · ownership.xml · nonDerivative · entry 2

PAKIANATHAN DEEPIKA · CIK 0001270734 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 3,385

F1 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $0.899 to $0.989, inclusive. The Reporting Person has provided to the issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price within the range.

F5 · ownership.nature: The shares are held directly by Delphi BioInvestments VIII, L.P. ("DB VIII"). DMP VIII is the general partner of each of DB VIII and DV VIII. The Reporting Person is a managing member of DMP VIII. As a managing member of DMP VIII, the Reporting Person shares voting and investment power over the securities held by DB VIII and DV VIII, and may be deemed to have indirect beneficial ownership of such shares. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his proportionate pecuniary interest therein.

SEC source: 0000950170-24-070991 · ownership.xml · nonDerivative · entry 1

PAKIANATHAN DEEPIKA · CIK 0001270734 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 346,615

F1 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $0.899 to $0.989, inclusive. The Reporting Person has provided to the issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price within the range.

F4 · ownership.nature: The shares are held directly by Delphi Ventures VIII, L.P. ("DV VIII"). Delphi Management Partners VIII, L.L.C. ("DMP VIII"), is the general partner of each of DB VIII and DV VIII. The Reporting Person is a managing member of DMP VIII. As a managing member of DMP VIII, the Reporting Person shares voting and investment power over the securities held by DB VIII and DV VIII, and may be deemed to have indirect beneficial ownership of such shares. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his proportionate pecuniary interest therein.

SEC source: 0000950170-24-068969 · ownership.xml · nonDerivative · entry 6

PAKIANATHAN DEEPIKA · CIK 0001270734 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 7,911

F3 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $0.93 to $0.9985, inclusive. The Reporting Person has provided to the issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price within the range.

F5 · ownership.nature: The shares are held directly by Delphi BioInvestments VIII, L.P. ("DB VIII"). DMP VIII is the general partner of each of DB VIII and DV VIII. The Reporting Person is a managing member of DMP VIII. As a managing member of DMP VIII, the Reporting Person shares voting and investment power over the securities held by DB VIII and DV VIII, and may be deemed to have indirect beneficial ownership of such shares. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his proportionate pecuniary interest therein.

SEC source: 0000950170-24-068969 · ownership.xml · nonDerivative · entry 5

PAKIANATHAN DEEPIKA · CIK 0001270734 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 810,133

F3 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $0.93 to $0.9985, inclusive. The Reporting Person has provided to the issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price within the range.

F4 · ownership.nature: The shares are held directly by Delphi Ventures VIII, L.P. ("DV VIII"). Delphi Management Partners VIII, L.L.C. ("DMP VIII"), is the general partner of each of DB VIII and DV VIII. The Reporting Person is a managing member of DMP VIII. As a managing member of DMP VIII, the Reporting Person shares voting and investment power over the securities held by DB VIII and DV VIII, and may be deemed to have indirect beneficial ownership of such shares. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his proportionate pecuniary interest therein.

SEC source: 0000950170-24-068969 · ownership.xml · nonDerivative · entry 4

PAKIANATHAN DEEPIKA · CIK 0001270734 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 11,209

F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $0.9643 to $1.06, inclusive. The Reporting Person has provided to the issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price within the range.

F5 · ownership.nature: The shares are held directly by Delphi BioInvestments VIII, L.P. ("DB VIII"). DMP VIII is the general partner of each of DB VIII and DV VIII. The Reporting Person is a managing member of DMP VIII. As a managing member of DMP VIII, the Reporting Person shares voting and investment power over the securities held by DB VIII and DV VIII, and may be deemed to have indirect beneficial ownership of such shares. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his proportionate pecuniary interest therein.

SEC source: 0000950170-24-068969 · ownership.xml · nonDerivative · entry 3

PAKIANATHAN DEEPIKA · CIK 0001270734 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 1,147,875

F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $0.9643 to $1.06, inclusive. The Reporting Person has provided to the issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price within the range.

F4 · ownership.nature: The shares are held directly by Delphi Ventures VIII, L.P. ("DV VIII"). Delphi Management Partners VIII, L.L.C. ("DMP VIII"), is the general partner of each of DB VIII and DV VIII. The Reporting Person is a managing member of DMP VIII. As a managing member of DMP VIII, the Reporting Person shares voting and investment power over the securities held by DB VIII and DV VIII, and may be deemed to have indirect beneficial ownership of such shares. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his proportionate pecuniary interest therein.

SEC source: 0000950170-24-068969 · ownership.xml · nonDerivative · entry 2

PAKIANATHAN DEEPIKA · CIK 0001270734 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 14,697

F1 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $0.9308 to $0.9996, inclusive. The Reporting Person has provided to the issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price within the range.

F5 · ownership.nature: The shares are held directly by Delphi BioInvestments VIII, L.P. ("DB VIII"). DMP VIII is the general partner of each of DB VIII and DV VIII. The Reporting Person is a managing member of DMP VIII. As a managing member of DMP VIII, the Reporting Person shares voting and investment power over the securities held by DB VIII and DV VIII, and may be deemed to have indirect beneficial ownership of such shares. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his proportionate pecuniary interest therein.

SEC source: 0000950170-24-068969 · ownership.xml · nonDerivative · entry 1

PAKIANATHAN DEEPIKA · CIK 0001270734 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 1,505,131

F1 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $0.9308 to $0.9996, inclusive. The Reporting Person has provided to the issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price within the range.

F4 · ownership.nature: The shares are held directly by Delphi Ventures VIII, L.P. ("DV VIII"). Delphi Management Partners VIII, L.L.C. ("DMP VIII"), is the general partner of each of DB VIII and DV VIII. The Reporting Person is a managing member of DMP VIII. As a managing member of DMP VIII, the Reporting Person shares voting and investment power over the securities held by DB VIII and DV VIII, and may be deemed to have indirect beneficial ownership of such shares. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his proportionate pecuniary interest therein.

SEC source: 0000950170-24-066785 · ownership.xml · derivative · entry 1

PAKIANATHAN DEEPIKA · CIK 0001270734 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 69,000

Underlying: Common Stock · 69,000 shares

Expires 2034-05-28

F1 · derivative.exercise_date: This option vests as to 100% of the underlying shares on May 29, 2025.

SEC source: 0001415889-24-012919 · form4-05102024_100512.xml · derivative · entry 2

PAKIANATHAN DEEPIKA · CIK 0001270734 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 23,576

Underlying: Ordinary Shares · 23,576 shares

Expires 2034-05-07

F1 · derivative.exercise_date: This option may be exercised and shall be vested as to 1/12th of the shares subject to this option when optionee completes each continuous month of service following the grant date and any then remaining unvested shares shall vest on the date of the next annual meeting of the company's shareholders provided the optionee remains in continuous service on such date.

SEC source: 0001415889-24-012919 · form4-05102024_100512.xml · nonDerivative · entry 1

PAKIANATHAN DEEPIKA · CIK 0001270734 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 47,416

SEC source: 0000950170-24-013271 · ownership.xml · derivative · entry 1

PAKIANATHAN DEEPIKA · CIK 0001270734 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 45,000

Underlying: American Depository Shares · 45,000 shares

Expires 2034-02-08

F1 · derivative.exercise_date: Vests in substantially equal monthly installments over a one year period from the February 8, 2024 grant date.

F2 · derivative.underlying: Each American Depositary Share ("ADS") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer.

SEC source: 0001209191-23-032149 · doc4.xml · derivative · entry 1

PAKIANATHAN DEEPIKA · CIK 0001270734 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 34,000

Underlying: Common Stock · 34,000 shares

Expires 2033-05-23

F1 · derivative.exercise_date: This option vests as to 100% of the underlying shares on May 24, 2024.

SEC source: 0001415889-23-007384 · form4-05042023_100524.xml · derivative · entry 2

PAKIANATHAN DEEPIKA · CIK 0001270734 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 22,044

Underlying: Ordinary Shares · 22,044 shares

Expires 2033-05-01

F1 · derivative.exercise_date: This option may be exercised and shall be vested as to 1/12th of the shares subject to this option when optionee completes each continuous month of service following the grant date and any then remaining unvested shares shall vest on the date of the next annual meeting of the company's shareholders provided the optionee remains in continuous service on such date.

SEC source: 0001415889-23-007384 · form4-05042023_100524.xml · nonDerivative · entry 1

PAKIANATHAN DEEPIKA · CIK 0001270734 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 36,879

SEC source: 0000899243-23-003071 · doc4.xml · nonDerivative · entry 2

PAKIANATHAN DEEPIKA · CIK 0001270734 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · Delphi BioInvestments VIII, L.P.

Disclosed balance after: 0

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.36 to $0.41, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

F3 · ownership.nature: The reported securities were directly held by Delphi BioInvestments VIII, L.P. ("DBI VIII"). DMP VIII is the general partner of DBI VIII and was deemed to have sole voting and dispositive power over the securities held by DBI VIII. Douglas A. Roeder, James J. Bochnowski, David L. Douglass and Deepika R. Pakianathan, Ph.D. are the managing members of DMP VIII and were deemed to share voting and dispositive power over the securities held by DBI VIII. Such persons and entities disclaim beneficial ownership of the securities held by DBI VIII, except to the extent of any pecuniary interest therein.